Clover Health Investments (CLOV) Stock: Buy, Sell, or Hold?
CLOV - Clover Health Investments, Corp
$4.56
-0.10 (-2.15%)
âŧ
5d:
+5.07%
30d:
+6.79%
90d:
-7.69%
WAIT
LOW Confidence
Analysis Updated: Sep 16, 2026 12:00 AM ET
Earnings: Nov 03, 2026
Get Alerted When CLOV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CLOV is fairly priced but lacks strong directional signals. At -7.0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CLOV is fairly priced but lacks strong directional signals. At -7.0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CLOV is currently trading at $4.56, which is considered slightly high relative to its 30-day fair value range of $4.14 to $4.62. From a valuation perspective, the stock is trading at a discount (Forward PE: 28.8) compared to its historical average (35.7). Remarkably, the market is currently pricing in an annual earnings decline of 7.0% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, CLOV is in a downtrend. Immediate support is located at $4.12, while resistance sits at $5.18.
Market Sentiment: CLOV scores 13/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.38 (+17.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CLOV is in a downtrend. Immediate support is located at $4.12, while resistance sits at $5.18.
Market Sentiment: CLOV scores 13/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.38 (+17.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$4.14 -
$4.62
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
40.5%
Protect Your Profits
Holding CLOV? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Weak technical setup (13/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($5.38)
- WARNING: Composite score 39/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.14 -
$4.62
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$4.12
Resistance Level
$5.19
Current Trend
Downtrend
Technical data as of
Sep 16, 2026
Fundamental Context
Forward P/E (Next Year Est.)
28.79
Wall Street Target
$5.38
(+17.9%)
Revenue Growth (YoY)
55.6%
Profit Margin
-0.7%
Valuation Discount vs History
-7.0% cheaper
PE vs Historical
28.8 vs 35.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.0%
(market-implied from PE analysis)
1-Year Target
$4.24
(-7%)
2-Year Target
$3.94
(-14%)
3-Year Target
$3.67
(-20%)
3-Yr Target (if PE normalizes)
(PE: 29â36)
$4.55
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 28.8, Growth: 59.0%)
$15.39
(+238%)
Base:
(SPY PE: 20.2, Growth: 59.0%)
$10.79
(+137%)
Bear:
(PE: 17.2, Growth: 59.0%)
$9.17
(+101%)
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 28.8 to 35.7
Stabilization Target:
$5.65
(+24.0%)
PE Expansion Potential:
+24.0%
Share & Embed Analysis
Last updated: September 17, 2026 12:43 AM ET
Data refreshes hourly during market hours. Next update: 1:43 AM
Data refreshes hourly during market hours. Next update: 1:43 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CLOV showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Healthcare Plans Stocks
Top-rated stocks in Healthcare Plans by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CVS
CVS Health Corp |
STRONG BUY
28 analysts |
$116 | 56 HOLD |
|
UNH
UnitedHealth Group IncorâĻ |
STRONG BUY
27 analysts |
$475 | 47 HOLD |
|
CI
Cigna Corp |
STRONG BUY
25 analysts |
$339 | 52 HOLD |
|
ELV
Elevance Health Inc |
STRONG BUY
22 analysts |
$450 | 38 SELL |
|
HUM
Humana Inc |
HOLD
26 analysts |
$419 | 52 HOLD |
Advanced CLOV Option Strategies
Professional options setups generated by AI based on today's CLOV price and gamma walls.
